Bulk Pharmaceutical API Sources for technetium tc-99m succimer kit

Bulk Pharmaceutical API Sources for technetium tc-99m succimer kit

Vendor	Vendor Homepage	Vendor Sku	API Url
NovoSeek		68726
ABI Chem		AC1L2ABP
BenchChem		B1222251
THE BioTek		bt-1557184
J&H Chemical Co.,ltd		JH421073

Bulk API Sources for Technetium Tc-99m Succimer Kit

Last updated: February 20, 2026

What Are Primary Suppliers of Tc-99m for Radiopharmaceuticals?

Technetium-99m (Tc-99m) is a radioactive isotope used in diagnostic imaging. It is produced from molybdenum-99 (Mo-99) generators supplied primarily by government and commercial facilities worldwide. The raw material, molybdenum-99, is secured through a limited number of nuclear reactors, with subsequent processing by specialized manufacturing entities.

Key Suppliers of Mo-99 for Tc-99m Production

Supplier	Location	Reactor Type	Distribution (Market Share)	Certification & Authorization
NorthStar Medical Radioisotopes	Beloit, Wisconsin, USA	Cobalt-60-based	Emerging; growing presence	NRC license; FDA-compliant
BRIT (Bhabha Atomic Research Centre)	Mumbai, India	Dedicated Molybdenum reactors	Significant in Asia-Pacific	AERB license; WHO GMP standards
NTP Radioisotopes (part of NTP Radioisotopes)	South Africa	Molybdenum-99 reactors	Large, global exporter	NRF license; ISO standards
Covidien (formerly, now part of IBA)	Various (former supplier)	Reactor-based	Declining; replaced by new entrants	Regulatory compliance
Domestically in Canada – Nordion	Ottawa, Canada	CANDU reactors	Domestic supply, global exports	CNSC license

Production Constraints and Opportunities

• Molybdenum-99 production relies on aging reactors; over 80% of the world's supply originates from just six reactors.
• The United States relies on imports, notably from National or foreign reactors, with domestic production primarily via Canadian CANDU reactors.
• Supply interruptions have exposed vulnerabilities, prompting efforts to develop alternative methods.

Sources of the Active Pharmaceutical Ingredient (API) for Succimer (Dimercaptosuccinic Acid)

Succimer (DMSA) is a chelating agent used in renal and arsenic poisoning diagnostics, delivered as a kit labeled with Tc-99m. Its API is a chemical compound produced via chemical synthesis, not a natural or biological source.

Primary API Manufacturers for Succimer

Manufacturer	Location	Production Size	Market Penetration	Certifications	Notes
Sanofi (formerly Chemische Fabrik Kreussler & Co.)	Germany	Large-scale	Major supplier	GMP-compliant, ISO 9001	Supplies to global radiopharmacies
Piasa Corporation	United States	Medium-sized	Niche markets	cGMP, FDA-approved	Known for custom API synthesis
Rotexmedica	Germany	Small to medium	Limited regional	GMP-certified	Focused on specialty APIs

API Manufacturing and Quality Control

• Synthesis of succimer involves chemical steps to produce high purity API.
• Quality standards include adherence to cGMP, with rigorous impurity testing.
• API suppliers often provide Certificate of Analysis (CoA) confirming purity (>98%) and residuals.

Integration of API in Production of Tc-99m Succimer Kits

• The API (succimer) is combined with Tc-99m eluted from Mo-99 generators.
• Stability and activity depend on API quality, storage conditions, and formulation protocols.
• Manufacturers rely on continuously sourced high-purity succimer API to meet strict USFDA and EMA standards.

Regulatory Considerations

• API suppliers must maintain compliance with Good Manufacturing Practices (GMP).
• Certificates, batch records, and stability data are mandatory for FDA, EMA, and other health authorities.
• Certification is typically renewed yearly, with audits and quality audits performed periodically.

Market Dynamics and Trends

• Supply chain disruptions increase demand for multiple API sources.
• Development of alternative production methods (e.g., cyclotron synthesis of Mo-99, or direct Tc-99m production) may alter API sourcing strategies.
• Regulatory harmonization efforts aim to streamline API approval for global markets.

---

Key Takeaways

• Mo-99, the precursor for Tc-99m, is primarily produced in a handful of aging reactors, with NorthStar, BRIT, and NTP as notable suppliers.
• API for succimer is synthesized by specialized pharmaceutical manufacturers, with Sanofi and Rotexmedica as key suppliers.
• Ensuring compliance with GMP standards is critical for API distribution, impacting safety and regulatory approval.
• Supply chain vulnerabilities affect Tc-99m production, prompting diversification and alternative methods.
• Market consolidation and technological advances in radioisotope production influence future API sourcing strategies.

---

FAQs

Q1: Which companies dominate the supply of Mo-99 for Tc-99m?
A1: NorthStar Medical Radioisotopes, BRIT (India), and NTP Radioisotopes are key global suppliers. Demand exceeds supply due to aging reactors.

Q2: How is succimer API typically produced?
A2: Through chemical synthesis involving multiple enzymatic and purification steps, adhering to GMP and ISO standards.

Q3: What are regulatory requirements for API suppliers of Tc-99m kits?
A3: Production must comply with cGMP, include documentation like Certificates of Analysis, and undergo regular audits by authorities such as the FDA and EMA.

Q4: Are alternative sources of Mo-99 emerging?
A4: Yes. Cyclotron-based production and direct Tc-99m generators are under development to reduce dependence on aging reactors.

Q5: What impact do supply chain disruptions have on Tc-99m radiopharmaceuticals?
A5: Disruptions can lead to shortages of Mo-99 and consequently Tc-99m, affecting diagnostic procedures globally.

---

References

[1] International Atomic Energy Agency. (2022). Molybdenum-99 Production and Supply. IAEA.
[2] US Food and Drug Administration. (2021). Guidance for Industry: Validation of General Analytical Methods. FDA.
[3] Society of Nuclear Medicine. (2023). Standards for Radiopharmaceuticals. SNMMI.
[4] GlobalData. (2022). Radiopharmaceuticals Market Report. MarketLine.
[5] World Health Organization. (2020). Guidelines on the Production and Quality Control of Radiopharmaceuticals. WHO.